EMAS position statement: Managing menopausal women with a personal or family history of VTE |
| |
Authors: | Tremollieres Florence Brincat Marc Erel C Tamer Gambacciani Marco Lambrinoudaki Irene Moen Mette H Schenck-Gustafsson Karin Vujovic Svetlana Rozenberg Serge Rees Margaret;European Menopause and Andropause Society |
| |
Institution: | 1. Florence Tremollieres Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse Cedex 09, France;2. Department of Obstetrics and Gynaecology, Mater Dei Hospital, B’Kara, NXR2130, Malta;3. Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No: 93/4, Nisantasi, 34365 Istanbul, Turkey;4. University of Pisa, Department of Obstetrics and Gynecology, Via Roma 67, 56100 Pisa, Italy;5. 2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GR-11528 Athens, Greece;6. Department of Laboratory Medicine, Children''s and Women''s Health, Faculty of Medicine, Norwegian University of Science and Technology, NO-7491 Trondheim, Norway;g Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital, NO-7006 Trondheim, Norway;h Department of Medicine, Cardiology Unit and Head Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:06, SE 17176 Stockholm, Sweden;i Institute of Endocrinology, Clinical Center of Serbia, Belgrade School of Medicine, Dr Subotica 13, 11000 Beograd, Serbia;j Department of Obstetrics &; Gynecology, CHU ST Pierre. Université Libre de Bruxelles, 1000 Brussels, Belgium;k Women''s Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK |
| |
Abstract: | IntroductionVenous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), is a serious cardiovascular event whose incidence rises with increasing age.AimsTo formulate a position statement on the management of the menopause in women with a personal or family history of VTE.Material and methodsLiterature review and consensus of expert opinion.Results and conclusionsRandomized controlled trials have shown an increased risk of VTE in oral hormone therapy (HT) users. There are no randomized trial data on the effect of transdermal estrogen on VTE. Recent observational studies and meta-analyses suggest that transdermal estrogen does not increase VTE risk. These clinical observations are supported by experimental data showing that transdermal estrogen has a minimal effect on hepatic metabolism of hemostatic proteins as the portal circulation is bypassed. A personal or family history of VTE, especially in individuals with a prothrombotic mutation, is a strong contraindication to oral HT but transdermal estrogen can be considered after careful individual evaluation of the benefits and risks. Transdermal estrogen should be also the first choice in overweight/obese women requiring HT. Observational studies suggest that micronized progesterone and dydrogesterone might have a better risk profile than other progestins with regard to VTE risk. Although these findings should be confirmed by randomized clinical trials, they strongly suggest that both the route of estrogen administration and the type of progestin may be important determinants of the overall benefit-risk profile of HT. |
| |
Keywords: | Venous thromboembolism Pulmonary embolism Menopausal women |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|